UDP-glycosyltransferases (UGTs) catalyze the covalent addition of sugars to a broad range
of lipophilic molecules. This biotransformation plays a critical role in elimination of a broad …

Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …

Herbs are often administered in combination with therapeutic drugs, raising the potential of
herb-drug interactions. An extensive review of the literature identified reported herb-drug …

UDP-glucuronosyltransferase (UGT) enzymes catalyze the conjugation of various
endogenous substances (eg, bilirubin) and exogenous compounds (eg, drugs). The human …

Purpose Interest in the use of herbal products has grown dramatically in the Western world.
Recent estimates suggest an overall prevalence for herbal preparation use of 13% to 63 …

Objectives SN-38, an active metabolite of irinotecan, is detoxified by glucuronidation with
UGT1A isoforms, 1A1, 1A7, 1A9, and 1A10. The pharmacogenetic information on UGT1A …

A number of therapeutic drugs with different structures and mechanisms of action have been
reported to undergo metabolic activation by Phase I or Phase II drug-metabolizing enzymes …

Purpose: Capecitabine and irinotecan are commonly used in the treatment of metastatic
colorectal cancer (CRC). We hypothesized that germline polymorphisms within genes …

Purpose: The purpose was to explore the relationships between irinotecan disposition and
allelic variants of genes coding for adenosine triphosphate binding cassette transporters …

Purpose A comprehensive haplotype analysis of UGT1A1 in the Japanese population was
conducted, and the effects of these haplotypes were investigated with respect to UGT1A1 …